Organellar and cellular stress are induced during immunogenic cell death (ICD), a particularly functional response pattern. ICD is a separate but poorly characterized entity caused by various cancer treatments. The induction of ICD has the potential to change TME and the recruitment of tumor-...
Abbreviations: CPI, Checkpoint Inhibitor; HCPCS, Healthcare Common Procedure Coding System; NDC, National Drug Codes; ICD-9/10-CM, International Classification of Disease, Ninth or Tenth Revision, Clinical Modification; CPT, Current Procedureal Terminology; NSCLC, non-small cell lung cancer; PET, ...
Brahmer, J.; Horn, L.; Hossein, B.; Ramalingam, S.; Pluzanski, A.; Burgio, M.; Garassino, M.; Chow, L.; Gettinger, S.; Crino, L.; et al. O.02 Long-term Survival Outcomes with Nivolumab (NIVO) in Pts with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC): ...
Data regarding the association between photodynamic therapy (PDT) and mortality in lung cancer patients are limited. We analyzed the association between PDT and mortality in patients with stage III or IV non-small cell lung cancer (NSCLC) using data from
Figure 4. Distribution of Initial Treatment by NSCLC Stage (SEER-18, 2016) View LargeDownload NSCLC indicates non–small cell lung cancer; SEER-18, Surveillance, Epidemiology, and End Results. A, for all ages; B, for those younger than 65 years; and C, those aged 65 years or older. Mu...
Each patient had an ICD-9 or ICD-10 diagnosis of lung cancer (162.x or C34.x), at least 2 documented clinical visits on or after January 1, 2011, pathology consistent with nonsquamous NSCLC, and confirmation of advanced NSCLC on or after January 1, 2011. All patients received at least...
Non-Small Cell Lung CancerTobaccoSmokingObesityBackground: Obesity is an emerging leading cause of morbidity and mortality in the US and the relationship between obesity, tobacco, and survival in NSCLC is unclear. Methods: Data (n = 87,631) were obtained from linkage of the 1996-2007 Florida ...
Only a history of economic instability (by ICD10 code) was associated with a lower likelihood of getting sotorasib (OR 0.22, 95% CI 0.03-0.91).Conclusions:In this cohort, KRAS G12C appears to confer a favorable prognosis compared to non-G12C variants, which may be explained in part by...
Phase I/II study of a 3 weekly oral taxane (DJ-927) in patients with recurrent, advanced non-small cell lung cancer.[J].Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 2008,7(7)....
Each patient had an ICD-9 or ICD-10 diagnosis of lung cancer (162.x or C34.x), at least 2 documented clinical visits on or after January 1, 2011, pathology consistent with nonsquamous NSCLC, and confirmation of advanced NSCLC on or after January 1, 2011. All patients received at least...